Funding for this research was provided by:
Ministero della Salute (Ricerca Corrente 2017-2019, Ricerca Corrente 2017-2019, Ricerca Corrente 2017-2019)
Era-Net Biomiga project
Received: 5 July 2022
Accepted: 10 August 2022
First Online: 17 September 2022
: The study was approved by the local Ethics Committee of Pavia, Italy (P-20190105434). All patients signed a written informed consent before enrollment. The study procedures were carried out following the guidelines for proper human research conduct in accordance with the Helsinki Declaration of the World Medical Association and its revisions.
: Not applicable.
: RDI: honoraria for scientific presentations from Eli-Lilly, and Teva. MA: honoraria for scientific presentations from Eli-Lilly. CT: personal fees for scientific presentations or participation in advisory boards from Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis and Teva; PI or collaborator in clinical trials sponsored by Abbvie, Alder, Amgen, Eli-Lilly, IBSA, Lundbeck, Novartis and Teva; grants from the European Commission, the Italian Ministry of Health and the Italian Ministry of University and Research, Migraine Research Foundation, Abbvie; GS: honoraria for the participation in advisory boards or for oral presentations from: Eli-Lilly, Novartis and Teva. GV, NG, EG, DM, LA, MC, FB, FT, SB, FC: nothing to declare.